A liquid biopsy that measures treatment response up to 8 weeks before a routine radiographic assessment.1
>50% reduction in ctDNA is associated with significantly longer progression-free
For patients with
between progression and
Results in under
Assess response to therapy 4-10
weeks after treatment initiation.3
Molecular responders had significantly longer
PFS vs non-responders.1
On-treatment ctDNA dynamics are:
an early predictor of long-term
benefits of therapy1
complementary to standard imaging1
PFS by Cancer Type
Predict treatment response 8 weeks
before standard imaging.2
across the cancer continuum.
Easy access to test ordering and
management with simple order forms.
Clear, concise reports.Sign in now ›
Easy and Convenient Sample Collection
A mobile phlebotomy service makesInquire about mobile phlebotomy ›
sample collection as easy and
convenient as possible by meeting
patients at their location.
Important Note: The Guardant360 Response and Guardant360 tests were developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant360 Response refers to Guardant360 Response Laboratory Developed Test (LDT) and Guardant360 refers to the Guardant360 LDT. These tests have not been cleared or approved by the US FDA. Guardant360 CDx is not approved by the US FDA to assess treatment response or long-term survival.
*Samples submitted >20 weeks after the baseline blood draw will not be accepted.
For a full list of diagnoses, download the Controlled Language for Diagnosis page.
00321 3. Guardant360® Response: Guide to ordering Guardant360 Response. Guardant Health, Inc. Palo Alto, CA. 4. Raja R, Kuziora M, Brohawn PZ, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018;24(24):6212-6222. doi:10.1158/1078-0432.CCR-18-0386 5. Modi S, Andre F, Krop IE, et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. ASCO Annual Meeting. 2020. doi/abs/10.1200/JCO.2020.38.15
_suppl.1036 6. Maron SB, Chatila WK, Millang BM, et al. Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): plasma and tumor-based biomarker analysis. J Clin Oncol. 2020;38(suppl 15):4559. doi:10.1200/JCO.2020.38.15_suppl.4559